KPNA3: A Potential Drug Target and Biomarker for Parkinson's Disease

Target Name: KPNA3

NCBI ID: G3839

KPNA3

KPNA3: A Potential Drug Target and Biomarker for Parkinson's Disease

Parkinson's disease is a neurodegenerative disorder that affects millions of people worldwide. It is characterized by motor symptoms such as tremors, rigidity, and bradykinesia, which can significantly impact an individual's quality of life. Despite advances in treatment, the underlying cause of Parkinson's disease remains unresolved, and there is a high demand for new and effective therapies.

Recent studies have identified a potential drug target for Parkinson's disease, KPNA3, which is a subunit of the importin alpha-4 protein. KPNA3 plays a critical role in the transportation of dopamine (a critical neurotransmitter) to its target in the brain, which is thought to contribute to the symptoms of Parkinson's disease.

The Importin alpha-4 protein is a transmembrane protein that plays a central role in intracellular signaling. It is composed of four subunits, including KPNA3, which is involved in the regulation of intracellular signaling pathways, including the cAMP/protein kinase A (PKA) signaling pathway. This pathway is involved in the regulation of a wide range of cellular processes, including protein synthesis, cell signaling, and neurotransmitter transport.

In Parkinson's disease, the levels of KPNA3 are decreased, and this has been associated with the dysfunction of the importin alpha-4 protein. Studies have shown that decreased KPNA3 levels is associated with increased levels of dopamine, which is a known risk factor for Parkinson's disease. Additionally, inhibition of the importin alpha-4 protein has been shown to protect dopamine-dependent neurons from neurotoxicity in Parkinson's disease.

The drug target for Parkinson's disease is KPNA3, which is a subunit of the importin alpha-4 protein. KPNA3 plays a critical role in the transportation of dopamine to its target in the brain, which is thought to contribute to the symptoms of Parkinson's disease.

In conclusion, KPNA3 is a potential drug target and biomarker for Parkinson's disease. The study of KPNA3 and its role in the importin alpha-4 protein is a promising direction for future research in the development of new treatments for Parkinson's disease. Further studies are needed to fully understand the function of KPNA3 and its potential as a drug target.

Protein Name: Karyopherin Subunit Alpha 3

Functions: Functions in nuclear protein import as an adapter protein for nuclear receptor KPNB1. Binds specifically and directly to substrates containing either a simple or bipartite NLS motif. Docking of the importin/substrate complex to the nuclear pore complex (NPC) is mediated by KPNB1 through binding to nucleoporin FxFG repeats and the complex is subsequently translocated through the pore by an energy requiring, Ran-dependent mechanism. At the nucleoplasmic side of the NPC, Ran binds to importin-beta and the three components separate and importin-alpha and -beta are re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran from importin. The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus. In vitro, mediates the nuclear import of human cytomegalovirus UL84 by recognizing a non-classical NLS. Recognizes NLSs of influenza A virus nucleoprotein probably through ARM repeats 7-9

The "KPNA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KPNA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets